TY - JOUR
T1 - Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients
T2 - Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation
AU - Kelly, Debra Lynch
AU - Buchbinder, David
AU - Duarte, Rafael F.
AU - Auletta, Jeffrey J.
AU - Bhatt, Neel
AU - Byrne, Michael
AU - DeFilipp, Zachariah
AU - Gabriel, Melissa
AU - Mahindra, Anuj
AU - Norkin, Maxim
AU - Schoemans, Helene
AU - Shah, Ami J.
AU - Ahmed, Ibrahim
AU - Atsuta, Yoshiko
AU - Basak, Grzegorz W.
AU - Beattie, Sara
AU - Bhella, Sita
AU - Bredeson, Christopher
AU - Bunin, Nancy
AU - Dalal, Jignesh
AU - Daly, Andrew
AU - Gajewski, James
AU - Gale, Robert Peter
AU - Galvin, John
AU - Hamadani, Mehdi
AU - Hayashi, Robert J.
AU - Adekola, Kehinde
AU - Law, Jason
AU - Lee, Catherine J.
AU - Liesveld, Jane
AU - Malone, Adriana K.
AU - Nagler, Arnon
AU - Naik, Seema
AU - Nishihori, Taiga
AU - Parsons, Susan K.
AU - Scherwath, Angela
AU - Schofield, Hannah Lise
AU - Soiffer, Robert
AU - Szer, Jeff
AU - Twist, Ida
AU - Warwick, Anne
AU - Wirk, Baldeep M.
AU - Yi, Jean
AU - Battiwalla, Minoo
AU - Flowers, Mary E.
AU - Savani, Bipin
AU - Shaw, Bronwen E.
N1 - Funding Information:
The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration; 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Alexion; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; Perkin Elmer, Inc.; Pfizer, Inc; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Asterisk denotes Corporate Members.
Funding Information:
The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI) , the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases ; a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration ; 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research ; and grants from * Actinium Pharmaceuticals ; Alexion ; * Amgen, Inc. ; Anonymous donation to the Medical College of Wisconsin ; Astellas Pharma US ; AstraZeneca ; Atara Biotherapeutics, Inc. ; Be The Match Foundation ; * Bluebird Bio, Inc. ; * Bristol Myers Squibb Oncology ; * Celgene Corporation ; Cellular Dynamics International, Inc. ; Cerus Corporation ; * Chimerix, Inc. ; Fred Hutchinson Cancer Research Center ; Gamida Cell Ltd. ; Genentech, Inc. ; Genzyme Corporation ; Gilead Sciences, Inc. ; Health Research, Inc. Roswell Park Cancer Institute ; HistoGenetics, Inc. ; Incyte Corporation ; Janssen Scientific Affairs, LLC ; * Jazz Pharmaceuticals ; Jeff Gordon Children's Foundation ; Leukemia and Lymphoma Society ; Medac, GmbH ; MedImmune ; The Medical College of Wisconsin ; * Merck & Co., Inc. ; * Mesoblast; MesoScale Diagnostics, Inc. ; * Miltenyi Biotec, Inc. ; National Marrow Donor Program ; Neovii Biotech NA, Inc. ; Novartis Pharmaceuticals Corporation ; Onyx Pharmaceuticals ; Optum Healthcare Solutions, Inc. ; Otsuka America Pharmaceutical, Inc. ; Otsuka Pharmaceutical Co, Ltd. – Japan ; PCORI ; Perkin Elmer, Inc. ; Pfizer, Inc ; * Sanofi US ; * Seattle Genetics ; * Spectrum Pharmaceuticals, Inc. ; St. Baldrick's Foundation ; * Sunesis Pharmaceuticals, Inc. ; Swedish Orphan Biovitrum, Inc. ; Takeda Oncology ; Telomere Diagnostics, Inc. ; University of Minnesota ; and * WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Asterisk denotes Corporate Members.
Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2018/2
Y1 - 2018/2
N2 - Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.
AB - Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.
KW - Bone marrow transplantation
KW - Cognition
KW - Cognitive function
KW - Hematology oncology
KW - Hematopoietic cell transplantation
KW - Neurocognitive dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85034852162&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.09.004
DO - 10.1016/j.bbmt.2017.09.004
M3 - Review article
C2 - 28939455
AN - SCOPUS:85034852162
SN - 1083-8791
VL - 24
SP - 228
EP - 241
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 2
ER -